Dr. Martens (DOCS) H1 2026 earnings summary

Executive summary

• Strategic shift to a consumer-first approach, focusing on full-price sales, reduced markdowns, and expanding product and market reach, with strong brand momentum and early results from new growth levers.

• Progressing on FY26 objectives with cost control, execution, and a focus on becoming the most desired premium footwear brand.

• Only 0.7% share in top 15 markets, indicating significant headroom for growth.

• Launched new product families (Buzz, Zebzag, Lowell, 1460 Rain Boot) and expanded distribution partnerships in LATAM, UAE, and Asia.

• Technology investments include a new customer data platform, supply-demand system, and a Global Technology Centre in India.

Financial highlights

• Group revenue was £322.0m, down 0.8% reported but up 0.8% at constant currency; DTC revenue flat at CC, wholesale up 2% CC.

• Gross margin improved to 65.3% (up 1.3pts YoY), driven by higher full-price mix and cost control.

• Adjusted EBIT returned to positive at £3.1m (vs. £-3.0m prior year); EBITDA increased 47.1% to £35.9m.

• Net bank debt reduced by £33m year-over-year to £154.3m; total debt including leases down £46m to £302m.

• Interim dividend maintained at 0.85p per share, formulaic at one-third of prior year full dividend.

Outlook and guidance

• Trading in line with expectations; FY26 adjusted PBT consensus range is £53m–£60m, excluding tariff impacts.

• FY26 guidance: 20–25 new store openings, capex around £20m, net debt c.£200m including leases, inventory flat year-over-year.

• Tariffs expected to be a high single-digit £m headwind in FY26, with about half mitigated; full mitigation by FY27 and beyond.

• Currency expected to be a £10m headwind to revenue and £2m benefit to adjusted PBT.

• Wholesale order books for SS26 are healthy, especially in Americas.